NBFCs will outperform banks over the next two-three quarters, and even two-three years.
Even last quarter, we were a bit disappointed, but this one may not be as good at all.
But in the last two-three quarters, we have seen a very good order position, new molecules coming into play and the company seems to have got its rhythm back as well.
But I do not think that just because of the RBI statement, one should get underweight NBFCs per se.
On the longer-term basis, NBFCs will outperform banks over the next two-three quarters, two-three years as well.

Overweight on pharma as a quarterly trade; NBFCs to outperform banks long term: Dipan Mehta